MORGAN HILL, California – July 11, 2016: Aragen Bioscience, Inc. (Aragen), leading pre-clinical contract research organization specializing in the discovery and early development of high-value biologics and diagnostic products has appointed Oren Beske, Ph.D. as the President of Aragen Bioscience.
Dr. Beske joined Aragen Bioscience in 2007 as Director, In Vitro Services and has held various leadership positions in the company. Most recently he has served as the Chief Operating Officer and went on to be the Chief Technology and Business Officer.
Manni Kantipudi, Chairman of Aragen Bioscience, commented “After an extensive search for a new President, Dr. Beske was the clear choice to lead Aragen forward. I am pleased that he has accepted this responsibility to drive the growth, strategy and delivery at Aragen.”
“With Aragen’s strong technical capabilities, a diverse client base and the backing of GVK BIO, it is poised for growth and to make a significant impact on the contract research industry. I very pleased to have been selected to lead Aragen into this very exciting next phase”, added Oren Beske, Ph.D. President of Aragen Bioscience.
For more information please visit www.aragenbio.com
Phone: +1 408 779 1700
About Aragen Bioscience
Aragen Bioscience, Inc. (Aragen, Morgan Hill, CA, USA) is a privately held contract research organization with offices and laboratories in the San Francisco Bay Area. Aragen Bioscience offers a diverse set of in vitro and in vivo services for the discovery, characterization, activity assessment and early development of biologic and diagnostic products. More information on Aragen Bioscience, Inc. can be found at www.aragenbio.com